

**NATIONAL CLINICAL GUIDELINE: MANAGEMENT OF PAEDIATRIC DIABETIC KETOACIDOSIS**

DOC TITLE: General Principles in the Management of Paediatric Diabetic Ketoacidosis

VERSION NO: v2 E F F E C T I V E FROM DATE: 28/06/2025 REVISION DUE DATE: 28/06/2028



National Policy  National Procedure  National Protocol  National Guideline   
 National Clinical Guideline

**HSE National Clinical Guideline**  
 General Principles in the Management of Paediatric Diabetic Ketoacidosis

**DOCUMENT GOVERNANCE <sup>1</sup>**

<b>Document Owner (post holder title):</b>	National Clinical Lead for Paediatric Diabetes
<b>Document Owner name:</b>	Prof Michael O Grady
<b>Document Owner email contact:</b> <i>(Generic email addresses only for the Repository)</i>	<a href="mailto:clinicaldesign@hse.ie">clinicaldesign@hse.ie</a>
<b>Document Commissioner(s): (Name and post holder title):</b>	Dr Ciara Martin, National Clinical Advisor and Group lead for Children and young People
<b>Document Approver(s): (Name and post holder title):</b>	Dr Ciara Martin, National Clinical Advisor and Group lead for Children and young People
<b>Lead responsibility for national implementation:</b>	National Clinical Programme for Paediatrics and Neonatology Paediatric Diabetes Working Group
<b>Lead responsibility for national monitoring and audit:</b>	National Clinical Programme for Paediatrics and Neonatology Paediatric Diabetes Working Group
<b>Development Group Name:</b>	National Clinical Programme for Paediatrics and Neonatology Paediatric Diabetes Working Group
<b>Development Group Chairperson:</b>	Prof Michael O Grady

*Additional headings can be inserted as required*

**DOCUMENT MANAGEMENT <sup>2</sup>**

<b>Date effective from:</b>	28/06/2025		
<b>Date set for next review:</b>	28/06/2028		
<b>Your Reference No: (if applicable)</b>	CDI/0113/2.0/2025		
<b>Current version no:</b>	2	<b>Archived version no:</b>	1

Note: Original document is Version 0. First revision is Version 1. Second revision is Version 2, and so on.

Note: HSE National 3PGs should be formally reviewed every 3 years, unless new legislative/regulatory or emerging issues/research/technology/audit etc. dictates sooner.

## NATIONAL CLINICAL GUIDELINE: MANAGEMENT OF PAEDIATRIC DIABETIC KETOACIDOSIS

DOC TITLE: General Principles in the Management of Paediatric Diabetic Ketoacidosis

VERSION NO: v2 E F F E C T I V E FROM DATE: 28/06/2025 REVISION DUE DATE: 28/06/2028

<b>VERSION CONTROL UPDATE</b> <sup>3</sup>		
<b>Version No.</b> <small>(most recent version first)</small>	<b>Date reviewed</b> <small>(most recent date first)</small>	<b>Comments</b> <small>(1 sentence max, if required)</small>
V2	June 2025	Minor update to no 7.7.7 on page 12
V1	August 2024	Minor Edits applied to all sections. Appendix added
V0	Published October 2020	(Original document) Unique identifier – Ref: CSP008/2019
<b>Document management notes:</b>		
<ol style="list-style-type: none"> <li>1. Minor modifications in spelling, some terminology updated and formatting throughout the document</li> <li>2. Addition of Appendix on page 18- Quick ED Guide</li> <li>3. Change of wording to no. 7.7.7 on page 12</li> </ol>		
<b>PUBLICATION INFORMATION</b> <sup>4</sup>		
<b>Topic:</b>		
General Principles in the Management of Paediatric Diabetic Ketoacidosis		
<b>National Group:</b>		
National Clinical Programme for Paediatrics and Neonatology Paediatric Diabetes Working Group		
<b>Short summary:</b>		
The aim of this guideline is to provide clear and standardised guidelines for all staff caring for paediatric patients with type 1 diabetes in relation to the recognition and management of diabetic ketoacidosis.		
<b>Description:</b>		
<p>The purpose of this guideline is to improve the management of paediatric diabetic ketoacidosis (DKA). It is intended for healthcare professionals, particularly those in training, who are working in HSE-funded paediatric and neonatal services and is designed to guide clinical judgement but not replace it. In individual cases a healthcare professional may, after careful consideration, decide not to follow the guideline if it is deemed to be in the best interests of the child.</p> <p>Severe DKA is the commonest cause of diabetes-related deaths in children and adolescents. Most deaths in DKA occur in young people as a result of cerebral oedema. Treatment is distinctly different from adults because of the risk of cerebral oedema. Prevention of DKA by earlier diagnosis at onset of diabetes, immediate referral and support for those challenged by diabetes self-care is the goal. Optimal management of established DKA is key to reducing morbidity and mortality.</p>		



## NATIONAL CLINICAL GUIDELINE

### General Principles in the Management of Paediatric Diabetic Ketoacidosis

Clinical Design and Innovation Health  
Service Executive

Developed by:	National Clinical Programme for Paediatric Diabetes	Publication date V0 :	October 2020
Document Reference Numberv1:	CDI/0113/2.0/2025	Publication date V1:	January 2025
Document Reference Numberv2	CDI/0113/2.0/2025	Publication date V2:	June 2025

## Contents

1.0	Aim of Guideline.....	5
2.0	Purpose and Scope .....	5
3.0	Background and Introduction .....	5
4.0	Legislation/Other Related Policies .....	5
5.0	Glossary of Terms and Definitions.....	6
6.0	Roles & Responsibilities .....	6
7.0	Clinical Guideline .....	6
7.1	General Resuscitation .....	6
7.2	Confirm Diagnosis .....	7
7.3	Initial Management.....	8
7.4	Fluid Management .....	8
7.5	Fluid type .....	9
7.6	Potassium: .....	10
7.7	Insulin .....	11
7.8	Bicarbonate.....	12
7.9	Sodium and Osmolality .....	12
7.10	Monitoring during therapy .....	13
7.11	Additional Considerations for the Severely Unwell Child in ICU .....	13
7.12	Cerebral Oedema .....	14
8.0	Implementation, revision and audit .....	15
9.0	References .....	16
10.0	Qualifying Statement.....	17
11.0	Appendices .....	18
	Appendix 1 Blood and Urine Monitoring .....	18
	Appendix 2 Controversies .....	18
	Appendix 3 Quick ED Guide to Paediatric DKA.....	19
	Appendix 4 Acknowledgements .....	20
	Appendix 5 Guideline Approval .....	21

## 1.0 Aim of Guideline

The aim of this guideline is to provide clear and standardised guidelines for all staff caring for paediatric patients with type 1 diabetes in relation to the recognition and management of diabetic ketoacidosis.

## 2.0 Purpose and Scope

**2.1** The purpose of this guideline is to improve the management of paediatric diabetic ketoacidosis (DKA). These DKA guidelines are intended for use in children with :

- Acidosis - pH < 7.3 OR Std Bicarbonate < 18mmol/L
- Ketosis (> 3 mmol/L) OR ketonuria (moderate/large)
- Hyperglycaemia - plasma glucose > 11 mmol/L, glycosuria
- > 5% dehydration
- ± vomiting
- ± drowsy

**2.2** This guideline is intended for healthcare professionals, particularly those in training, who are working in HSE-funded paediatric and neonatal services. It is designed to guide clinical judgement but not replace it.

**2.3** In individual cases a healthcare professional may, after careful consideration, decide not to follow a guideline if it is deemed to be in the best interests of the child.

## 3.0 Background and Introduction

Severe DKA is the commonest cause of diabetes-related deaths in children and adolescents. Most deaths in DKA occur in young people as a result of cerebral oedema. Treatment is distinctly different from adults because of the risk of cerebral oedema. Prevention of DKA by earlier diagnosis at onset of diabetes, immediate referral and support for those challenged by diabetes self-care is the goal. Optimal management of established DKA is key to reducing morbidity and mortality.

## 4.0 Legislation/Other Related Policies

**4.1** Model of Care for All Children and Young People with Type 1 Diabetes (2015)

[http://www.hse.ie/eng/about/Who/clinical/natclinprog/paediatricsandneonatology/paeds\\_moc.pdf](http://www.hse.ie/eng/about/Who/clinical/natclinprog/paediatricsandneonatology/paeds_moc.pdf)

## 5.0 Glossary of Terms and Definitions

**AVPU** (an acronym for) Alert, Voice, Pain, Unresponsive

**DKA** Diabetic ketoacidosis

**GCS** Glasgow Coma Scale

**ED** Emergency Department

## 6.0 Roles & Responsibilities

**6.1** This guideline should be reviewed by each hospital's senior management team to appropriately plan implementation. This will ensure that the inpatient care of children/neonates admitted to their facility is optimised irrespective of location.

**6.2** Each unit requires clear arrangements that identify the resources and area where a child with DKA is safely managed. This should be communicated to all staff that care for paediatric patients.

## 7.0 Clinical Guideline

The goals of therapy in DKA are to:

- Correct acidosis and reverse ketosis
- Correct dehydration
- Restore blood glucose to near normal
- Monitor for complications of DKA and its treatment
- Identify and treat any precipitating event

### 7.1 General Resuscitation

**7.1.1** **Airway** - ensure that airway is patent and secure airway if child is comatose. Pass N/G tube, on free drainage, if comatose (GCS <9 or AVPU – not responding to voice) or persistent vomiting.

**7.1.2** **Breathing** - 100% Oxygen via face mask

**7.1.3** **Circulation** - 2 large bore IV cannulae, take baseline bloods (see 7.2.3)

- If child is volume depleted but not shocked, give 10mL/kg 0.9% w/v Sodium Chloride over 30 mins (as a bolus)

In children who weigh >100kg, maximum bolus is 1L as per adult protocols.

- Reassess capillary refill time and heart rate
- +/- repeat bolus 10mL/kg 0.9% w/v Sodium Chloride

- Senior input is required if considering need for a third bolus of 10mL/kg 0.9% w/v Sodium Chloride (See **Appendix 2**)

**REMEMBER**

- **Children can die from DKA. Always discuss these children with the Consultant Paediatrician/Consultant Paediatric Endocrinologist on call.**
- **Paediatric Endocrinology should also be consulted for management advice for child with hyperosmolar, non-ketotic acidosis and for management of neonatal diabetes**

## 7.2 Confirm Diagnosis

7.2.1 **History:** polydipsia, polyuria, weight loss, vomiting, abdominal pain, drowsiness, hyperventilation (note what fluids the child has been drinking as if large volumes of very sweet fluids (e.g. sugar-sweetened beverage) have been consumed, initial glucose may be very high and may fall rapidly once insulin is commenced)

7.2.2 **Clinical assessment (needs to be reviewed at regular intervals):** acidotic respirations, dehydration, drowsiness (record GCS), focus of infection, ileus. DKA does not cause pyrexia. If febrile, look for underlying infection (e.g. urinalysis, CXR, blood cultures etc.).

### 7.2.3 Bloods

- ✓ Venous glucose (>11mmol/L),
- ✓ Fingerprick (point of care) ketones (Use and Interpretation of blood ketone testing **Appendix 1**)
- ✓ Venous Gas (pH <7.3)
- ✓ Electrolytes (closely monitor potassium, corrected sodium and renal function)
- ✓ FBC (neutrophilia is common as component of stress response)
- ✓ Calculate corrected sodium and effective osmolality (see 7.9)

If a new patient, send samples for:

- ✓ *HbA1c* (1.2mL EDTA),
- ✓ *TFT* (1.2mL serum) and *anti-TPO* (1.2mL serum),
- ✓ *anti-GAD*, *ZnT8*, *IAA* and *anti-IA2 antibodies* (1.2mL serum to Exeter),
- ✓ IgA and TTG (1.2 mL serum)

### Urine

Urinalysis – check for ketones

### 7.3 Initial Management

7.3.1 **Check weight:** It is almost always possible to measure weight of the child in DKA and is much safer for calculating fluid/insulin requirements.

If not possible (child is unconscious), use recent clinic weight or estimated weight from centile chart. Actual weight should be confirmed as soon as possible.

APLS calculation (weight in kg = 2 (age+4) is valid for pre-pubertal children; Note APLS now provide weight charts and are generally available in Resuscitation areas.

7.3.2 **Record consciousness level:** (Use GCS).

7.3.3 **Assess degree of dehydration:** overestimation of dehydration is dangerous. Do not use more than 8% dehydration in calculations.

% Dehydration	Clinical Features
Mild (3%)	Only just clinically detectable
Moderate (5%)	Dry mucous membranes, reduced skin turgor
Severe (8%)	Above, with sunken eyes and poor capillary return.
<b>+SHOCK</b>	May be severely ill with poor perfusion, thready rapid pulse (hypotension is unlikely and a VERY late sign)

7.3.4 **ECG Monitor:** (T wave changes). Children require continuous cardiorespiratory monitoring until acidosis is corrected.

7.3.5 **Consider ICU admission:** if severe DKA (pH < 7.1, hyperventilation, shock, depressed level of consciousness, persistent vomiting, age < 2 years) or if staffing on ward is insufficient to allow adequate monitoring.

7.3.6 **Physical examination:** look for evidence of cerebral oedema, infection or Ileus

### 7.4 Fluid Management

7.4.1 At this stage, circulating volume should have been restored (see Resuscitation 7.1)

7.4.2 Once circulating volume is restored:

$$\text{Requirements} = \text{Maintenance} + \text{Deficit}$$

7.4.3 Calculate Maintenance fluids: see table ( \*Neonates generally requires higher fluid rates and management of DKA in neonates is specialised and needs to be in conjunction with Paediatric Endocrinology)

Weight (kg)	Maintenance fluid (ml/kg/24h)
<12.9*	80
13-19.9	65
20-34.9	55
35-59.9	45
>60	35

**Calculate Deficit (litres) =**

% dehydration (Use % for calculations maximum of 8%) X Body weight (kg) Note that 1kg = 1000mL for calculations.

Worked Example
20kg child with 5% dehydration
$20 \times 0.05 = 1 \text{ kg} = 1000\text{mL deficit}$

7.4.4 Add 48 hour Maintenance to Deficit and subtract any initial emergency rehydration that may have been administered (e.g. 10mL/kg boluses)

7.4.5 Give total volume evenly over 48 hours.

Worked Example	
25 kg 6year old boy who is 10% dehydrated who has received fluid bolus of 0.9% w/v Sodium Chloride 10mL/Kg in E.D	
<b>Maintenance</b>	55mL X 25kg = 1375mL (over 24hrs) 2750mL (over 48h) Plus
<b>Deficit</b>	0.08 (max is 8%) X 25kg = 2 (litres)2000mL
Subtract	
<b>Resuscitation Bolus</b>	-250mL
<b>Total Fluids Required over 48 hours</b>	4500mL
<b>Rate ml per hour</b>	93.7 mL/hr

**7.5 Fluid type**

- 7.5.1 0.9% w/v Sodium Chloride with 20 mmol/L potassium chloride /500mL is recommended initial fluid type and fluids may be adjusted depending on patient’s hydration status, sodium and osmolality. Glucose may be added to the 0.9% w/v Sodium Chloride as required (see 7.5.4- 7.5.5)
- 7.5.2 Potassium should be added once passing urine or renal profile result confirms not hyperkalaemic.\* see also 7.6.1 below
- 7.5.3 Aim for gradual decrease in plasma glucose of 4-5mmol/L per hour

## NATIONAL CLINICAL GUIDELINE: MANAGEMENT OF PAEDIATRIC DIABETIC KETOACIDOSIS

- 7.5.4 If blood glucose is dropping at  $>5\text{mmol/L}$  per hour **OR** blood glucose  $< 17\text{mmol/L}$ , **add 5% w/v glucose to the 0.9% w/v sodium chloride**
- Increase glucose concentration** added to 0.9% w/v sodium chloride fluids to 7.5% if blood glucose continues to fall at  $>5\text{mmol/L}$  per hour **OR** blood glucose is less than  $8\text{mmol/L}$
- Increase glucose concentration** added to 0.9% w/v sodium chloride in fluids to 10% if blood glucose continues to fall  $>5\text{mmol/L}$  per hour **OR** blood glucose is less than  $8\text{mmol/L}$
- 7.5.5 If blood glucose continues to drop when patient is maintained on 0.9% w/v Sodium Chloride and 10% w/v glucose, consider reducing insulin infusion rate (see 7.7.6). This normally will not occur until ketones have cleared
- 7.5.6 Excessive continuing on-going losses might need to be replaced if the severity of dehydration is not improving after review and discussion with Consultant Paediatrician/Endocrinologist
- 7.5.7 **Oral fluids** – Keep nil PO. Re-introduce oral fluids **gradually** after substantial clinical improvement and correction of acidosis and subtract from total fluid required (IV calculations)

### 7.6 Potassium:

- 7.6.1 Total body Potassium is always depleted in DKA although initial serum potassium levels may be low, normal or elevated. Potassium levels will fall once insulin is commenced
- 7.6.2 Commence potassium supplements  $20\text{mmol}$  potassium chloride per  $500\text{ mL}$  of fluid as soon as initial resuscitation is completed (unless anuria is suspected or peaked T-waves on ECG)
- 7.6.3 Monitor electrolytes 2 hourly twice after start of resuscitation and then 2-4 hourly until DKA corrected and adjust K replacement accordingly
- 7.6.4 Continue ECG monitoring during resuscitation

## 7.7 Insulin

### INSULIN ADMINISTRATION SAFETY ALERT

**INSULIN ERRORS CAN HAVE EXTREMELY SERIOUS CONSEQUENCES**-always act on healthcare professional concerns re doses and recheck

-

- Overdoses can cause severe hypoglycaemia, seizures, coma and even death
- Under dosage can result in diabetic ketoacidosis.

Please **INDEPENDENTLY DOUBLE CHECK** doses at each stage-

- When making up an infusion (an insulin syringe graduated in units to measure insulin must be used)
- When infusing via a pump
- When administering via pen (pens and cartridges are SINGLE PATIENT USE ONLY)

**ALWAYS CHECK PRESCRIPTION:**

- Reconfirm order with the prescriber if unsure/ concerned about the insulin dose
- Avoid abbreviations; insulin should be prescribed in units
- Do not administer an unclear prescription-Prescription **MUST** be rewritten

7.7.1 Insulin therapy should not be commenced until shock (if present) has been reversed by resuscitation, and should be deferred until IV fluids have been running for 1 hour **(this includes boluses, if administered)**

7.7.2 Continuous low dose insulin infusion is the optimal method. A programmable infusion pump, ideally with dose error reduction software (i.e. a 'smart-pump'), should be used

7.7.3 Insulin infusions should be prepared in a syringe at a standard concentration as determined by the child's weight. For all children weighing **5kg or more** a 1 unit/1mL solution should be prepared.

**Note:** For children weighing **less than 5kg** a more dilute concentration of 0.1unit/1mL must be prepared to ensure deliverable volumes. The care of small infants in DKA requires consultation with Paediatric Endocrinology.

### Insulin Infusion - for Children Weighing $\geq 5\text{kg}$

- Dilute 50 units (0.5mL) Actrapid® to a final volume of 50mL with Sodium Chloride 0.9%w/v. [This gives a solution containing 1 unit of insulin /mL]
- Connect via a Y connector to the fluids already running.
- Run the infusion at 0.1 units / kg / hour (0.1ml/kg/hr)\*
- Continue until pH >7.3 (\*\* Appendix 2)

\* Consideration can be given to use of a lower dose (0.05 units/kg/hour) in toddlers

## NATIONAL CLINICAL GUIDELINE: MANAGEMENT OF PAEDIATRIC DIABETIC KETOACIDOSIS

- 7.7.4 When glucose level <17mmol/L continue insulin at 0.1 units/kg/hr and commence (if not already running) glucose containing rehydration fluids (see 7.5.4)
- 7.7.5 Increase the glucose concentration (in steps up to 10%- see 7.5.4) before reducing insulin dose while acidosis correcting.
- 7.7.6 If glucose level continues to fall rapidly or level is below 8mmol/L when glucose 10% has been added to 0.9% w/v sodium chloride, decrease insulin to 0.05 units/kg/hr. Do not stop insulin infusion (until subcutaneous insulin commenced)
- 7.7.7 The child should be transitioned to subcutaneous insulin injections when acidosis is substantially corrected (e.g. pH > 7.3 or bicarbonate > 18 mmol/L). This typically occurs within the first 16- 24 hours of treatment. Mild acidosis (often due to hyperchloraemia) or mild ketosis (from fasting) should not be barriers to transitioning to subcutaneous insulin as both will resolve following oral intake and discontinuation of IV fluids. Subcutaneous insulin is given prior to a meal containing carbohydrate and insulin infusion and IV fluids are discontinued 20-30 mins after subcutaneous injection is given to prevent rebound hyperglycaemia.

**IF BIOCHEMICAL PARAMETERS DO NOT IMPROVE, REASSESS AND REVIEW FULLY (SEPSIS, OTHER DIAGNOSIS, ERRORS IN INSULIN PREPARATION, TISSUED IV LINE) AND RESTART PROTOCOL.**

### 7.8 Bicarbonate

- 7.8.1 There is no evidence that bicarbonate is either necessary or safe in the management of DKA. It may exacerbate CNS acidosis, tissue hypoxia and osmolar load. Its only purpose is to improve cardiac contractility in severe shock. Persistent acidosis usually reflects insufficient resuscitation, inadequate insulin or sepsis
- 7.8.2 Bicarbonate should only be considered if pH <6.9 and/or impaired cardiac contractility after discussion with senior medical staff

### 7.9 Sodium and Osmolality

- 7.9.1 A rapid fall in effective plasma osmolality and/or fall in sodium during therapy may be associated with cerebral oedema.
- 7.9.2 Where effective plasma osmolality is elevated in DKA, aim for slow correction over 24 hours (by 8 mmol/L/24h)
- Effective plasma osmolality =  $2X (Na^+ + K^+) + Glucose$**
- 7.9.3 Hyperglycaemia causes falsely low plasma sodium levels. Sodium should rise by 2mmol/l for every 5.5mmol/l fall in glucose and corrected sodium should be followed on a flow sheet

#### Corrected Sodium

$$\text{Measured Na}^+ + (2 \times (\text{glucose} - 5.5)) / 5.5$$

**NATIONAL CLINICAL GUIDELINE: MANAGEMENT OF PAEDIATRIC DIABETIC KETOACIDOSIS**

7.9.4 If corrected sodium fails to rise, and in particular if it falls during therapy, a careful re- evaluation of the fluid replacement is required. Consider slowing rate of rehydration, increasing sodium concentration and increase vigilance for signs of cerebral oedema

7.9.5 An initial serum Na of >150mmol/L might prompt an even slower rehydration rate than 48 hours

**7.10 Monitoring during therapy**

<b>Continuous</b>	<ul style="list-style-type: none"> <li>• ECG monitoring</li> </ul>
<b>½ Hourly</b>	<ul style="list-style-type: none"> <li>• neurological observations, including level of consciousness (using the modified Glasgow coma score) and heart rate, in children under the age of 2</li> <li>• or in children and young people with a pH less than 7.1, because they are at increased risk of cerebral oedema</li> </ul>
<b>1 hourly</b>	<ul style="list-style-type: none"> <li>• Vital signs (or more frequently as indicated)</li> <li>• Neuro observations (escalate immediately headache, change in conscious level or behaviour)</li> <li>• Blood glucose and blood ketone measurements</li> </ul>
<b>2 hourly*</b>	<ul style="list-style-type: none"> <li>• Electrolytes (x2) (and calculate corrected sodium)/VBG/ lab glucose until acidosis reversed</li> <li>• Review fluid composition and rate following each result</li> <li>• May be able to check 4 hourly after substantial clinical improvement</li> </ul>
<b>Accurate</b>	<ul style="list-style-type: none"> <li>• Documentation of fluid input and output.</li> </ul>
<b>Twice Daily</b>	<ul style="list-style-type: none"> <li>• Weights</li> </ul>

**7.11 Additional Considerations for the Severely Unwell Child in ICU**

7.11.1 Consider anticoagulant prophylaxis particularly in children with femoral lines

7.11.2 Urinary catheterisation should be avoided but may be required in the child with impaired consciousness. If urine output is inadequate (<1.5mL/kg/hr), the cause must be sought (e.g. acute renal failure, on-going shock, bladder outflow obstruction)

7.11.3 If fluid retention is occurring, there is some evidence that a single dose of a loop diuretic is helpful in promoting water diuresis

7.11.4 If a massive diuresis continues, fluid intake may need to be increased

7.11.5 If large volume of gastric aspirates continues, these may need to be replaced

7.11.6 If acidosis is not correcting, resuscitation may have been inadequate-consider (in conjunction with senior medical staff) giving a further bolus of 0.9% w/v Sodium Chloride (10mL/kg)

## 7.12 Cerebral Oedema

### THIS IS A LIFE-THREATENING EMERGENCY

The cause of cerebral oedema during therapy of DKA remains unclear. The results of a recent randomised controlled trial demonstrated that neither the rate nor the sodium chloride content of intravenous fluids significantly influenced neurologic outcomes in children presenting in DKA (please see Appendix 2 controversies for further details).

Early insulin administration (in the first hour of fluid management of DKA) has been shown to increase the risk of cerebral oedema so it is recommended that children receive fluids only in the first hour of treatment.

- Incidence 0.5-0.9% episodes of D.K.A. with 21-24 % mortality.
- Most commonly occurs in first 24 hours, usually 4-12 hours after treatment begins but may occur at 24-48 hours.
- More likely in younger children, first presentation, severe dehydration, more acidotic and longer duration of symptoms
- Pathophysiology of cerebral oedema in DKA is still poorly understood but epidemiological studies show greater risk when children are treated with insulin in the first hour of treatment
- Treat as such if any suspicion

**When managing children at high risk of cerebral oedema (low CO<sub>2</sub>, low pH, very high urea) mannitol dose should be calculated, drawn up and left at bedside.**

### 7.12.1 *Warning Signs/Symptoms*

7.12.1.0 Headache and slowing of heart rate

7.12.1.1 Change in neurological status (restlessness, irritability, increased drowsiness, incontinence (in a previously continent child) or specific neurological signs (e.g. cranial nerve palsies)

7.12.1.2 Rising BP, decreased O<sub>2</sub> saturations

7.12.1.3 Late signs such as seizures, papilloedema and respiratory arrest are associated with a very poor prognosis

### 7.12.2 *Management*

7.12.2.0 Contact Consultant Paediatrician/Endocrinologist and Anaesthetist immediately

7.12.2.1 Exclude hypoglycaemia as a cause of neurological deterioration

7.12.2.2 Mannitol\* or Hypertonic Sodium Chloride (2.7% or 3% ) need to be given as soon as possible

**Mannitol** - 0.5g – 1g/kg over 10-15mins equivalent to:

2.5mL – 5mL/kg of Mannitol **20% w/v**

**OR**

5mL – 10mL/kg of Mannitol **10% w/v**

*A repeated dose of mannitol may be required after 2 hours if no response*

**OR**

**Hypertonic Sodium Chloride**–: 1.25mmol/kg - 2.5mmol/kg (equivalent to 2.5mL -5 mL/kg of Sodium Chloride 3%w/v solution) over 10-15min (max single dose 75mmol (equivalent to 150mL)

- 7.12.2.3 Reduce maintenance fluid infusion rate by one third **and** also recalculate rehydration to deliver over 72 hours (instead of 48 hours)
- 7.12.2.4 Nurse at 45 degree angle
- 7.12.2.5 Transfer to PICU/ICU (if not there already) and consider need for transfer to tertiary PICU and consider need for ventilation (Note that aggressive hyperventilation to  $pCO_2 < 2.9kPa/22mmHg$  is associated with poorer outcome)
- 7.12.2.6 Consider either - Mannitol infusion - 0.25g/kg/hr or Mannitol 20%- 1g/kg every 6 hours
- 7.12.2.7 Consider imaging and Neurosurgical consult. CT/MRI is indicated (as other intracerebral pathology e.g. cerebral venous thrombosis, may occur and present in the same way)

## 8.0 Implementation, revision and audit

- 8.4 Distribution to the CEO/ General Manager for dissemination through line management in all acute hospitals
- 8.5 Implementation through Senior Management Teams of each acute hospital
- 8.6 Distribution to other interested parties and professional bodies
- 8.7 The NCPPN Diabetes Working group has agreed that this guideline will be reviewed on a **3** yearly basis.
- 8.8 Regular audit of implementation and impact of this guideline through outcome and process measures is recommended to support continuous quality improvement
- 8.9 It is the responsibility of each unit providing care for children with diabetes and intercurrent illness to audit the unit practice regularly in order to ensure that care is being provided in line with guidelines and that any deviations are clinically justified.
- 8.10 The audit process should be coordinated in each paediatric unit under local paediatric clinical governance and should be taken from a multidisciplinary perspective where appropriate
- 8.11 Where the audit identifies areas for practice improvement, it is the responsibility of each individual unit to implement changes and re-audit to support continuous quality improvement.

## 9.0 References

1. Wolfsdorf J, Glaser N et al. (2018). 'ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state.' *Pediatric Diabetes*. 2018 Oct; 19 Suppl 27:155-177. doi: 10.1111/pedi.12701.
2. Paediatric ED DKA Quick guide (2023)– Sligo University Hospital
3. Irish Medication Safety Network (2020) Best Practice Guidelines for the Safe Use of Insulin in Irish Hospitals <https://imsn.ie/wp-content/uploads/2020/07/insulin-best-practice-March-2020-with-appendices.pdf>
4. Kuppermann N, Ghetti S, et al, (2018). 'Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.' *The New England Journal of Medicine*, 2018 Jun 14; 378(24):2275-2287. doi: 10.1056/NEJMoa1716816

## 10.0 Qualifying Statement

1. These guidelines have been prepared to promote and facilitate standardisation and consistency of practice
2. Clinical material offered in this guideline does not replace or remove clinical judgement or the professional care and duty necessary for each child
3. Clinical care carried out in accordance with this guideline should be provided within the context of locally available resources and expertise
4. This Guideline does not address all elements of standard practice and assumes that individual clinicians are responsible for:
  - Discussing care with the child, parents/guardians and in an environment that is appropriate and which enables respectful confidential discussion.
  - Advising children, parents/guardians of their choices and ensure informed consent is obtained.
  - Meeting all legislative requirements and maintaining standards of professional conduct.
  - Applying standard precautions and additional precautions, as necessary, when delivering care.
  - Documenting all care in accordance with local and mandatory requirements.

## 11.0 Appendices

### Appendix 1 Blood and Urine Monitoring

- Blood Ketone strips measure Beta-hydroxybutyrate levels which account for 75-80% of circulating ketones in DKA are superior and recommended in DKA management; urine ketones measure acetone which is produced in relatively small quantities in DKA.
- Urine levels lag some hours behind blood levels.
- While the tests are measuring different ketones, the following may be useful:

Blood	Urine
<0.6 mmol/L	Negative
0.6-0.9 mmol/L	Trace
0.9-1.4 mmol/L	Small
1.5-2.4 mmol/L	Moderate
≥2.5 mmol/L	Large

### Appendix 2 Controversies

#### Controversy 1: Fluids in DKA: Outcome of RCT (2018)

A recent randomised control trial (conducted in 1289 episodes of DKA managed in a 13 paediatric centre network) examined the effects of the rate of administration and the sodium chloride content of IV fluids on neurologic outcomes in children with DKA. DKA episodes included had blood glucose level >16.7 mmol/l and either pH <7.25 or serum bicarbonate <15 mmol/l and presented with essentially intact neurological status (GCS >14). Mean age was 11.6 ± 4 years and all children were > 3 years of age. Children were randomly assigned to one of four groups (0.9% or 0.45% sodium chloride content and rapid or slow rate of administration). No significant differences were observed in GCS score, short term memory testing or clinically apparent brain injury in the 4 groups. While this study is very reassuring that rehydration rate and fluid type does not significantly affect cerebral oedema risk, the caveats are that no toddlers were included in this study and all children had GCS > 14 at recruitment. We therefore recommend maintaining a judicious approach to fluid management in DKA as above.

*Kuppermann N, Ghetti S, et al, (2018). 'Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.' The New England Journal of Medicine, 2018 Jun 14; 378(24):2275-2287. doi: 10.1056/NEJMoa1716816*

# Quick ED Guide to Paediatric DKA

Adapted from HSE National Clinical Guideline for Management of Paediatric Diabetic Ketoacidosis (2024)—please refer to full document.

## DIAGNOSIS

- D** Hyperglycaemia >11mmol/L AND
- K** Ketosis >3mmol/L, ketonuria AND
- A** Acidosis pH <7.3 OR Bicarb <18mmol/L

**Remember children can die from DKA. ALWAYS alert & discuss with the Consultant in Emergency Medicine and the Consultant Paediatrician.**

## INVESTIGATIONS

Bloods: EDTA + Serum + Glucose + VBG  
 PLUS IF first presentation: 1.2ml EDTA 1.2ml Serum x4  
 Urinalysis  
 ECG, CXR IF indicated

FBC, U+E, CRP & Glucose  
 +/- Blood cultures IF infection  
 HbA1c  
 TFTs, anti TPO, anti-GAD, ZnT8, anti-IA2 antibodies, IgA & TTG

## FLUIDS

**Initial Resus Fluids:** Bolus of 10ml/Kg NaCl 0.9% over 30mins, if child is volume depleted (ie: dehydration or shock). Contact Consultant. Further bolus if shocked, ensure consultant aware if further bolus needed.

**Maintenance Fluids:** Aim to replace fluids SLOWLY, over 48 hours, to avoid risk of cerebral oedema.

Weight (kg)	Maintenance fluid (ml/kg/24h)
<12.9	80
13-19.9	65
20-34.9	55
35-55.9	45
>60	35

$$= \boxed{\phantom{000}} \text{ ml} \times \boxed{\phantom{000}} \text{ Kg}$$

$$= \boxed{\phantom{000}} \text{ ml/24 hours} \times 2$$

$$= \boxed{\phantom{000}} \text{ ml/48 hours}$$

**Fluid Deficit:** % dehydration x body weight (Kg)

% Dehydration (MAX 8% fluid deficit)	
3%	Only just clinically detectable
5%	Dry mucous membranes, reduced skin turgor
8%	Sunken eyes, poor cap refill +/- SHOCK

$$= \boxed{\phantom{000}} / 100 \times \boxed{\phantom{000}} \text{ Kg}$$

$$= \boxed{\phantom{000}} \text{ Litres} \times 1000$$

$$= \boxed{\phantom{000}} \text{ mls}$$

**Requirement:** Commence potassium supplementation as soon as initial Resus completed, at required rate/hour:

48 hours maintenance PLUS Deficit MINUS Resus fluids given

$$\boxed{\phantom{000}} + \boxed{\phantom{000}} - \boxed{\phantom{000}} = \boxed{\phantom{000}} \text{ over 48 hours} = \boxed{\phantom{000}} \text{ per hour}$$

## POTASSIUM containing maintenance fluids

20mmol KCl per 500ml NaCl 0.9%

Add 20mmol KCl vial to 500ml NaCl 0.9% OR use premade bags if available

## INSULIN

Start Actrapid infusion at 0.05-0.1 unit/Kg/hour  
 Consider 0.05 unit/Kg/hour if <4 years old

Do NOT start insulin therapy until IV fluids (including boluses) have been running for AT LEAST one hour and SHOCK is reversed.

Add 50 units Actrapid to NaCl 0.9% to total 50ml. =1 unit/ml. Run at rate 0.05 - 0.1ml/Kg/hour

Aim for reduction in glucose of 4-5mmol/L per hour.

If rate of glucose fall is >5mmol/L per hour OR blood glucose <17mmol/L, add Dextrose 5% to NaCl 0.9% + KCl

If sugars continue to drop, see full guidance for complete Dextrose additions. Do NOT stop insulin. Do NOT change rate.

## OTHER HELPFUL TIPS

- Monitor Urine Output (avoid catheterisation if possible).
- Monitor for signs of cerebral oedema – see full guidance
- Monitor hourly vital signs, neuro obs, blood glucose and blood ketones. Place on telemetry.
- Monitor 2 hourly electrolytes, lab glucose, VBG.

## Appendix 4 Acknowledgements

This guideline has been developed by the National Clinical Programme for Paediatric and Neonatology Diabetes Working Group. The members of this group include medical, nursing and dietetic representatives from paediatric diabetes services. The Diabetes Working Group also wish to thank those who provided input and feedback on draft versions of this guideline throughout development, and those who provided valuable input during the consultation process and revision of the guideline.

Professor Michael O'Grady	National Clinical Lead Paediatric Diabetes, Consultant Paediatric Endocrinologist
Professor Colin Hawkes	Consultant Paediatric Endocrinologist
Professor Nuala Murphy	Consultant Paediatric Endocrinologist
Ms. Aisling Egan	Advanced Nurse Practitioner, Paediatric Diabetes
Dr Kate Gajewska	Health Promotion and Research Manager, Diabetes Ireland
Ms. Laura O'Shea	Senior Paediatric Diabetes Dietitian
Dr Orla Neylon	Consultant Paediatric Endocrinologist
Dr Vincent McDarby	Senior Paediatric Psychologist
Ms. Claire Maye	Advanced Nurse Practitioner, Paediatric Diabetes
Ms Jacqueline de Lacy	Programme Manager National Clinical Programme for Paediatrics and Neonatology and Paediatric Diabetes

## Appendix 5 Guideline Approval

Sign off by National Clinical Programme for Paediatric Diabetes Working Group	July	2020
Sign off by Paediatric Clinical Advisory Group, Faculty of Paediatrics, RCPI	August	2020
Sign off by National Clinical Advisory Group Lead (NCAGL), HSE	September	2020
Approved by the CCO CAG (23.10.2020)	October	2020
<b>Guideline Revised and updated (V1)</b>	<b>August</b>	<b>2024</b>
<b>Revised addition (V1) approved by Paediatric CAG</b>	<b>November</b>	<b>2024</b>
<b>Revised addition (V1) approved by NCAGL for Children and Young People</b>	<b>January</b>	<b>2025</b>
<b>Guideline (V1) revision on page 12</b>	<b>May</b>	<b>2025</b>
<b>Guideline (V2) published</b>	<b>June</b>	<b>2025</b>
<b>Guideline (V2) review date</b>	<b>June</b>	<b>2028</b>